Compounds > erlotinib hydrochloride
Page last updated: 2024-09-05

erlotinib hydrochloride and Allergic Cutaneous Angiitis

erlotinib hydrochloride has been researched along with Allergic Cutaneous Angiitis in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Biasco, G; Brandi, G; Dika, E; Maibach, H; Patrizi, A; Venturi, M1
Boeck, S; Heinemann, V; Wollenberg, A1

Other Studies

2 other study(ies) available for erlotinib hydrochloride and Allergic Cutaneous Angiitis

ArticleYear
Cutaneous leukocytoclastic vasculitis due to erlotinib: just an adverse event or also a putative marker of drug efficacy?
    Cutaneous and ocular toxicology, 2013, Volume: 32, Issue:4

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Erlotinib Hydrochloride; Humans; Liver Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; Vasculitis, Leukocytoclastic, Cutaneous

2013
Leukocytoclastic vasculitis during treatment with the oral EGFR tyrosine kinase inhibitor erlotinib.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:9

    Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Erlotinib Hydrochloride; Female; Humans; Leg; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Vasculitis, Leukocytoclastic, Cutaneous

2007